Growth hormone axis
Sermorelin
GRF 1-29 · formerly Geref · 29-aa · GHRH
A GHRH analog that was once a licensed medicine (Geref) before being withdrawn from the commercial market — now sourced only through unlicensed/compounded routes.
Reference status
Editorial research · independent review pending · 3 claims graded
What it is
Sermorelin is a shortened, active fragment of growth-hormone-releasing hormone. It was previously marketed as a licensed diagnostic and treatment product (Geref) before being discontinued commercially, not for safety reasons but for business ones.
It's now mainly available through US compounding pharmacies and research-chemical suppliers. The pharmacology (it does stimulate a real GH pulse) is well characterised from its earlier licensed history; the modern anti-ageing/recomp marketing goes well beyond what it was ever approved for.
The science, graded
What’s claimed — and how strong the evidence behind each claim actually is.
“Stimulates natural growth-hormone release”
Well characterised from its earlier licensed clinical history as a GH-stimulation test/treatment agent.
Claim-level citation mapping is in progress.
“Improves sleep, recovery and lean mass”
Commonly reported by users; not established in modern controlled outcome trials at marketed doses.
Claim-level citation mapping is in progress.
“A safer, 'more natural' alternative to HGH”
A relative claim without head-to-head trial support at typical community dosing.
Claim-level citation mapping is in progress.
Legal and regulatory context
Separate summaries for Great Britain, the United States, and the European Union. These are preliminary research summaries awaiting independent regional review; they are not legal determinations or advice.
Great Britain
Not currently a licensed medicine in the UK (its earlier licensed product was discontinued). No standard NHS or UK private-prescription route exists; what's sold now is an unlicensed/compounded or research-chemical product.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
United States
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
European Union
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- Buying medicines online · European Medicines Agency
What the community says
Positioned by the community as the 'gentler' entry point into the GH-secretagogue world, often for older users interested in recovery and sleep rather than physique extremes.
Where they’re talking
- r/PeptidesOften recommended as a first GH-axis peptide.
- TRT/hormone forumsDiscussed alongside broader hormone-optimisation routines.
References
- 1.Supply unlicensed medicinal products (specials) · MHRA
- 2.FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
- 3.Buying medicines online · European Medicines Agency